Highly potent mRNA based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effect. - Wikidata - awgldk - TriplyDB

Highly potent mRNA based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effect.

Highly potent mRNA based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effect.

http://www.wikidata.org/entity/Q39409268

about

Vaccine adjuvants: mode of action Therapeutic cancer vaccines: past, present, and future mRNA capping: biological functions and applications Adjuvant effects of a sequence-engineered mRNA vaccine: translational profiling demonstrates similar human and murine innate response Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection.An Enterovirus-Like RNA Construct for Colon Cancer Suicide Gene Therapy.Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa study Biomaterials for mRNA delivery.Antigen delivery to dendritic cells shapes human CD4+ and CD8+ T cell memory responses to Staphylococcus aureus Developing mRNA-vaccine technologies.Therapeutic efficacy in a hemophilia B model using a biosynthetic mRNA liver depot system.A novel, disruptive vaccination technology: self-adjuvanted RNActive(®) vaccines.Distinct transcriptional changes in non-small cell lung cancer patients associated with multi-antigenic RNActive® CV9201 immunotherapy.Prostate cancer vaccines.Cancer vaccination by electro-gene-transfer.Repositioning therapeutic cancer vaccines in the dawning era of potent immune interventions.Mobilizing and evaluating anticancer T cells: pitfalls and solutions.Nucleic acid vaccines: prospects for non-viral delivery of mRNA vaccines.A development that may evolve into a revolution in medicine: mRNA as the basis for novel, nucleotide-based vaccines and drugs Molecular insights into the development of T cell-based immunotherapy for prostate cancer.The ReNAissanCe of mRNA-based cancer therapy.Self-replicating alphavirus RNA vaccines.mRNA transcript therapy.Antigen-specific vaccines for cancer treatment.mRNA vaccine CV9103 and CV9104 for the treatment of prostate cancer.mRNA Cancer Vaccines.Messenger RNA vaccine based on recombinant MS2 virus-like particles against prostate cancer.Mechanism of action of mRNA-based vaccines.Bridging infectious disease vaccines with cancer immunotherapy: a role for targeted RNA based immunotherapeutics.Therapeutic Cancer Vaccines.CIMT 2014: Next waves in cancer immunotherapy--report on the 12th annual meeting of the Association for Cancer Immunotherapy: May 6–8 2014, Mainz, Germany.When transgenes shape immunity: cancer immune-gene therapy.mRNA vaccines - a new era in vaccinology.New Vaccine Technologies to Combat Outbreak Situations

P2860

Q21131210-BB60276C-9667-4244-A46B-90B11FE52C82 Q26863283-AF35FD4B-1DAB-4DB8-9AB1-272E39532139 Q27469050-0ABE2098-6822-4874-A4EB-0DA3F62C040D Q30397031-4E74A79F-D09A-4D1F-8AAF-DACAEC993C52 Q30423733-5E8A1587-C1F7-45EA-940B-7FCC62CF21E0 Q34478571-5E769D53-02F6-4637-9DBF-FCA09656C8D6 Q35746834-CD2329B8-1136-41A1-B5AF-2576BBB523A5 Q36271488-26DC0741-4D79-4BE2-909E-8B6C63A28114 Q36380959-98B653B0-4F62-454E-B29B-F6DAFCA5062E Q36684597-6EF26ED0-1F58-407A-A0AA-B679119938EA Q37330601-30553C60-E165-4F8B-91AE-2F3D089FA438 Q37530550-D35CFDC4-D1C7-4E98-8768-52C1116D1C28 Q37559326-F91F4291-1255-487F-89D4-4CA59672A671 Q38089935-7EF3670E-1C26-4E6E-8BDC-96A9DE2BD51D Q38143182-4A759AA7-C0FA-4A7F-90D5-C37415887DD9 Q38149916-1D053AED-3ED1-4C56-BB5A-20592F7CD14B Q38152795-B0B8092A-DE0E-4C10-A554-0C7FFDCF3224 Q38199151-FD7FCB78-1E5F-43A8-AF0D-24A325E76C1F Q38206520-E2356A39-56E9-4CFC-8EB6-2E2EDC867692 Q38254639-2ABCA169-F8D9-43AD-9BD6-61752B16315D Q38255012-BDCFDD63-ED6B-4B6C-BB38-E349723306BB Q38255634-8043B0EC-5E38-4E03-BB27-8E2CF57B750C Q38264088-4645A71B-8978-415F-A0E7-D3BEB46D5B75 Q38284692-40D60CFA-7F77-4E50-A0E8-DD4D6C26F754 Q38284699-8135B9AE-C9CF-4C1C-BC16-8F843E8B29D3 Q39013357-17212C64-7107-4BAE-98EB-222CCE441A5F Q39084400-3BB67E3C-AD4F-4CFD-9536-5836B4C05B17 Q39431058-58D25D92-97B1-4D5C-9183-AF1F1020FDA2 Q39829133-7AD481A9-B4E4-4A74-A617-45B1BC5F98D0 Q40728648-4103B63E-21EB-4CE2-9B4A-F3A296DBD42F Q42586718-E188B339-C8C3-44FD-927E-1343AEF21C8A Q45880014-CDDDD929-DE61-46C0-8C63-F0B5658521C1 Q47736893-E3BE243C-EA2D-4083-8938-38996B9E7079 Q57072744-41D069AE-E4ED-41D3-92EC-0197A0677B48

P2860

Highly potent mRNA based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effect.

http://www.wikidata.org/entity/Q39409268

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Highly potent mRNA based cance ...... n improved therapeutic effect.

@en

Highly potent mRNA based cance ...... n improved therapeutic effect.

@nl

type

label

Highly potent mRNA based cance ...... n improved therapeutic effect.

@en

Highly potent mRNA based cance ...... n improved therapeutic effect.

@nl

prefLabel

Highly potent mRNA based cance ...... n improved therapeutic effect.

@en

Highly potent mRNA based cance ...... n improved therapeutic effect.

@nl

P1433

Q39409268-3F2B16C5-0D97-4F2F-9636-89A7F9C8400A

P1476

Q39409268-8DE4CD3E-0DCF-45B8-B360-FECD20331B90

P2093

Q39409268-04492D16-EC5A-45B5-AB9F-8937A53561EF

Q39409268-255DB8F4-22AA-4390-BC4E-8AF731B8E562

Q39409268-5778439D-B822-48D4-AB42-BA7F07EC5407

Q39409268-B986BD1C-92CF-4E12-A513-B05E5D7F72B1

Q39409268-C2C2CAA3-8F6F-4A3E-8DC0-D9662A52234D

Q39409268-DB1DEFC5-1A09-4131-A5AF-F91771E6C928

Q39409268-F88D2981-DF01-4131-9A19-A081678439AB

P2860

Q39409268-01364AC3-F8FE-4E6D-A48A-1906621C82B3

Q39409268-0E01F3EC-F1B9-4467-9C38-1EA55C09B128

Q39409268-0F5641C8-574D-4733-83FF-823362E3EBDB

Q39409268-11E3AA69-B569-4D1A-A2AB-92CD7377EB36

Q39409268-1398A3CD-508A-40D3-906F-413A6EE0FAD0

Q39409268-1AD8FC00-1447-4D17-9F28-07A3967D063C

Q39409268-1E984A5D-8B5A-4CB5-9AD3-2512051A5AA8

Q39409268-20FE0277-4C5B-488B-B5C3-425A0EB8216A

Q39409268-250274BA-DCE5-4F43-B262-BCE22D90C2C1

Q39409268-28AD097A-A9C0-4AF8-94B7-FFE47B85FE9A

P304

Q39409268-02E9F646-0212-45F5-8379-A705E12D881C

P31

Q39409268-8B66E5E1-B549-4065-93CF-67B923F60155

P356

Q39409268-7BE7BA59-B73B-41DF-8067-B07C3225FDBB

P433

Q39409268-74663C62-C17C-4799-8E3E-7B1C412D5DF5

P478

Q39409268-96C40FD7-DF8E-4AB9-99E9-7460EC4BE261

P577

Q39409268-C78C1FA0-678F-4D39-98C1-4286691EB510

P5875

Q39409268-2E1D4E3B-FF47-46B7-AB9E-D7C74485DDF7

P698

Q39409268-28502A67-5CA3-4A68-9BBE-3593AAD2BF09

P356

P1433

Journal of Gene Medicine

P1476

Highly potent mRNA based cance ...... n improved therapeutic effect.

@en

P2093

Andreas Thess

http://www.w3.org/2001/XMLSchema#string

Christina Lorenz

http://www.w3.org/2001/XMLSchema#string

Kai Zanzinger

http://www.w3.org/2001/XMLSchema#string

Karl-Josef Kallen

http://www.w3.org/2001/XMLSchema#string

Katharina M Duchardt

http://www.w3.org/2001/XMLSchema#string

Mariola Fotin-Mleczek

http://www.w3.org/2001/XMLSchema#string

Regina Heidenreich

http://www.w3.org/2001/XMLSchema#string

P2860

Adoptive immunotherapy for cancer: building on success

Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501

A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer

Type, density, and location of immune cells within human colorectal tumors predict clinical outcome

In search of the 'missing self': MHC molecules and NK cell recognition

Immune checkpoint proteins: a new therapeutic paradigm for cancer--preclinical background: CTLA-4 and PD-1 blockade

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

Exploiting cross-priming to generate protective CD8 T-cell immunity rapidly.

Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice.

P304

428-439

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/JGM.2605

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P577

2012-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221764172

http://www.w3.org/2001/XMLSchema#string

P698

22262664

http://www.w3.org/2001/XMLSchema#string